Pancreatic Cancer Clinical Trials
Glufosfamide Phase III Clinical Trial for Pancreatic Cancer
Clinical trials are an important and necessary component of the drug development process, in order to evaluate the safety and efficacy of new drug candidates. The Eleison drug candidate Glufosfamide is being evaluated under a Phase III clinical protocol for certain patients with pancreatic cancer previously treated with gemcitabine. The trial is currently being conducted at leading hospitals and cancer treatment centers in United States, and later in this year in Europe and Asia. If you are interested in learning more about this clinical trial, please visit the US FDA Website
Physicians interested in learning more about or participating in Eleison’s clinical trials are invited to contact Eleison’s Chief Medical Officer, Dr. Forrest Anthony, by telephone at 215-554-3530, or by email at firstname.lastname@example.org
About Pancreatic Cancer
Pancreatic cancer (sometimes referred to as pancreatic adenocarcinoma) is one of the less common cancers, ranking as the 11th most common with 46,000 new cases in the U.S. in 2014, far fewer than breast, prostate, and lung cancers, each of with more than 200,000 new cases last year. Unfortunately, pancreatic cancer has a very poor prognosis and was the 4th most deadly cancer in the U.S., accounting for 40,000 deaths in 2014. Moreover, pancreatic cancer rates have been rising over the past 20 years or so, for reasons not currently understood. Because there are few early symptoms, and no effective diagnostic for early detection, most patients have relatively advanced disease at the time of diagnosis. Patients are treated with surgery if possible, and almost all patients receive chemotherapy. Gemcitabine is the only drug approved in the U.S. as monotherapy for the initial (first-line) treatment of pancreatic cancer, and has been the standard of care since 1996. More recently, two other drugs have been approved for use in combination with gemcitabine in first line treatment. No drugs are approved for second-line use, that is, when the disease progresses after gemcitabine treatment. Surgery alone rarely results in a cure, and even less frequently with chemotherapy. As a result, only 27% of patients survive their first year, and the five-year survival rate is a dismal 6%. Eleison’s Glufosfamide drug candidate is currently undergoing evaluation in patients with metastatic pancreatic cancer, as a second-line agent after treatment with a gemcitabine containing regimen. Glufosfamide is a molecule with a sugar component, and is designed to target cancer types that are highly metabolically active and requiring glucose for an energy source, such as pancreatic cancer.